

Katrina Otrubova

PATENT AGENT

Patents and
Innovations
San Diego

kotrubova@wsgr.com
858-350-2216

FOCUS AREAS

Intellectual Property
Life Sciences
Patents and Innovations

EXPERIENCE

Dr. Katerina Otrubova is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm's patents and innovations practice. She assists with the preparation and prosecution of patent applications in the chemistry, pharmaceuticals, and biotechnology fields.

Prior to joining the firm, Katerina was a postdoctoral fellow on the drug discovery team of the Skaggs School of Pharmacy at the University of California, San Diego. In this role, she focused on the screening of chemical libraries and on the design and synthesis of organic small molecules for the treatment of infectious diseases. During her doctoral work at The Scripps Research Institute in La Jolla, California, she developed small molecule inhibitors of fatty acid amide hydrolase, as well as new synthetic methodologies for small molecule libraries.

Katerina is a co-author on 16 peer-reviewed scientific articles and is a co-inventor on one U.S. patent application.

CREDENTIALS

Education

- Ph.D., Organic Chemistry, The Scripps Research Institute (TSRI)
- B.S., Chemistry, University of California, Berkeley

Associations and Memberships

- Member, San Diego Intellectual Property Law Association

Admissions

- U.S. Patent and Trademark Office

INSIGHTS

Select Publications

- Co-author with V. Srinivasan and D.L. Boger, "Discovery libraries targeting the major enzyme classes: The serine hydrolases," 24(16) *Bioorganic Medicinal Chemistry Letters* 3807-13, 2014
- Co-author with K.K. Duncan and D.L. Boger, "Chromane α -ketoheterocycle inhibitors of fatty acid amide hydrolase: An exploration of conformational constraints in the acyl side chain," 22(9) *Bioorganic Medicinal Chemistry Letters* 2763-70, 2014
- Co-author with B.F. Cravatt and D.L. Boger, "Design, synthesis, and characterization of γ -ketoheterocycles additionally targeting the cytosolic port Cys269 of fatty acid amide hydrolase," 57(3) *Journal of Medicinal Chemistry* 1079-89, 2014
- Co-author with M. Brown, S.T. O'Neal, R. C. Stevens, B. F. Cravatt, A.H. Lichtman, and D.L. Boger, "Rational design of fatty acid amide hydrolase (FAAH) inhibitors that act by covalently bonding to two active site residues," 135(16) *Journal of the American Chemical Society* 6289-99, 2013

- Co-author with D.L. Boger, " α -Ketoheterocycle-based inhibitors of fatty acid amide hydrolase (FAAH)," 3(5) *A.C.S. Chemistry Neurosciences* 340-8, 2012
- Co-author with G. Lushington, D. Vander Velde, K.L. McGuire, and S. R. McAlpine, "A comprehensive study of Sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines," 51(3) *Journal of Medicinal Chemistry* 530-44, 2008
- Co-author with K.L. McGuire and S.R. McAlpine, "Scaffold targeting drug-resistant colon cancers," 50(9) *Journal of Medicinal Chemistry* 1999-2002, 2007